Glenmark Pharmaceuticals informs about company updates

28 Nov 2017 Evaluate

Glenmark Pharmaceuticals has informed that the Baddi unit of the company underwent an US FDA audit from November 6, 2017 to November 11, 2017. The USFDA issued seven observations through the form 483. The company is in the midst of providing a comprehensive response to the observations and would be replying to the FDA shortly on the observations. At this point in time, the company has informed that the Baddi unit contributes approximately 10 percent of the revenue of US sales.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×